scholarly journals 18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer

2015 ◽  
Vol 11 (1) ◽  
pp. 316-322 ◽  
Author(s):  
HAKAN ÖZTÜRK ◽  
İNANÇ KARAPOLAT
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Radical Treatment ◽  
18F Fluorodeoxyglucose ◽  
Pet Ct ◽  
Fluorodeoxyglucose Pet

scholarly journals 18F-PSMA-1007 and 18F-fluorocholine PET/CT in prostate cancer progression diagnostics. First comparative experience

2019 ◽  
Vol 15 (3) ◽  
pp. 70-76
Author(s):  
N. A. Meshcheriakova ◽  
M. B. Dolgushin ◽  
A. I. Pronin ◽  
V. B. Matveev ◽  
A. A. Odzharova ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Specific Antigen ◽  
Bone Lesions ◽  
Prostate Cancer Progression ◽  
Radical Treatment ◽  
Positron Emission ◽  
Pet Ct ◽  
Computed Tomography Scans ◽  
Changes Detection

Background. Prostate cancer progression remains as a major problem among patients after their radical treatment. During last years a broad spectrum radiopharmaceuticals had developed to reveal the cause of biochemical recurrence.Objective: the comparison of 18F-fluorocholine and 18F-prostate-specific membrane antigen-1007 (18F-PSMA-1007) diagnostic abilities for the prostate cancer progression detection.Materials and methods. In this study had been included 18F-fluorocholine and 18F-PSMA-1007 PET/CT (positron emission tomography combined with computed tomography) scans of 9 patients after radical treatment with increased prostate-specific antigen (PSA) level (range 0.10–9.06 ng/ml).Results. 18F-PSMA-1007-PET/CT detected lesions in 7 (77.8 %) out of 9 patients, after radical prostatectomy and brachytherapy, in comparison with negative 18F-fluorocholine-PET/CT results in all cases.Conclusion. In this pilot study, 18F-PSMA-1007-PET/CT has showed high potential in pathological changes detection among patients with increased PSA level (minimum 0.10 ng/ml) and demonstrated the advantages in comparison with 18F-fluorocholine-PET/CT, especially in terms of revealing local recurrence and metastatic lymph nodes, as well as, in bone lesions early detection.

Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer

2011 ◽  
Vol 32 (6) ◽  
pp. 475-478 ◽  
Author(s):  
Paolo Castellucci ◽  
Chiara Fuccio ◽  
Maria Cristina Marzola ◽  
Adil Al-Nahhas ◽  
Domenico Rubello ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Primary Treatment ◽  
Biochemical Relapse ◽  
Choline Pet ◽  
Pet Ct

scholarly journals MP67-04 PREOPERATIVE 18F-FLUCICLOVINE PET/CT FINDINGS MAY BE PREDICTIVE OF POST-OPERATIVE PROSTATE-SPECIFIC ANTIGEN (PSA) IN PATIENTS WITH HIGH RISK PROSTATE CANCER

2020 ◽  
Vol 203 ◽  
pp. e1026
Author(s):  
Akinyemi Akintayo* ◽  
Olayinka Abiodun-Ojo ◽  
Mehrdad Alemozaffar ◽  
Oladunni Akin-Akintayo ◽  
Dattatraya Patil ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
High Risk Prostate Cancer ◽  
Ct Findings ◽  
Pet Ct ◽  
Risk Prostate Cancer

The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels

2017 ◽  
Vol 38 (2) ◽  
pp. 149-155 ◽  
Author(s):  
Levent Kabasakal ◽  
Emre Demirci ◽  
Jamal Nematyazar ◽  
Reşit Akyel ◽  
Baresh Razavi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Ct Imaging ◽  
Psma Pet ◽  
Pet Ct
Sign in / Sign up

Export Citation Format

Share Document